Tevogen Bio Holdings Inc. announced its artificial intelligence initiative, Tevogen.AI™, on May 30, 2025, designed to revolutionize immunotherapy development through advanced machine learning. With strategic partnerships from Microsoft and Databricks, Tevogen.AI integrates AI into its proprietary ExacTcell™ technology to enhance target identification, streamline clinical timelines, and reduce development costs for innovative therapies.
Tevogen.AI™ launches with patent-pending PredicTcell™ and AdapTcell™ technologies.
Partners with Microsoft for Azure AI and cloud, Databricks for data analytics.
Enhances immunotherapy for infectious diseases, cancers, and neurological disorders.
Expands headquarters to support dedicated AI data science team.
Aims to transform the $5 trillion U.S. healthcare sector.
Plans AI-driven clinical trial patient identification for efficiency.
Tevogen.AI™ integrates advanced machine learning with ExacTcell™, Tevogen’s platform for off-the-shelf, genetically unmodified T cell therapies. “Tevogen.AI’s vision extends beyond transforming how therapies are developed; it is expected to make a meaningful impact across multiple sectors of healthcare,” said Dr. Ryan Saadi, CEO of Tevogen. This initiative targets the $5 trillion U.S. healthcare market by addressing inefficiencies in therapy development.
PredicTcell™: Employs AI to predict immunologically active peptide complexes and their interactions with T cell receptors. Supported by a terabyte-scale database processing millions of protein interactions, it accelerates candidate selection and expands Tevogen’s pipeline across multiple diseases.
AdapTcell™: Decodes interactions between human leukocyte antigens (HLA) and T cells, unlocking insights into genetics and proteomics. It aims to build an HLA specificity map, enhancing immune response understanding and opening new therapeutic avenues.
Tevogen.AI collaborates with industry leaders to bolster its capabilities:
Microsoft: Provides Azure cloud infrastructure and AI expertise to accelerate drug discovery and enhance predictive modeling.
Databricks: Supplies specialized data engineering and analytics to refine AI models, improving predictive accuracy for immunotherapy development.
Tevogen is expanding its headquarters in Warren, N.J., to house a dedicated team of data scientists and engineers for Tevogen.AI. The initiative plans to extend its AI applications beyond immunotherapy, including clinical trial patient identification to drive efficiency and cost reduction. By combining proprietary technologies with robust partnerships, Tevogen.AI positions itself to lead in AI-driven healthcare innovation, delivering targeted therapies faster and more cost-effectively.
TechIntelPro empowers B2B technology decision-makers with the latest industry trends, deep insights, leadership perspectives and actionable intelligence to drive both organizational and professional milestones—and thrive on the tech pulse.